Table 6.
SBRT versus TACE: Retrospective studies.
| Author | Arm | Number of Patients | Local Control 2–3 Years (%) |
p (after PSM) |
Survival 2–3 Years (%) (after PSM) |
p (after PSM) |
Complications (%) |
p |
|---|---|---|---|---|---|---|---|---|
| Sapir [46] | SBRT | 125 | 91.3 | (<0.001) | 34.9 | (0.21) | Grade ≥ 3, 13 | 0.05 |
| TACE | 84 | 22.9 | 54.9 | Grade ≥ 3, 8 | ||||
| Shen [47] | SBRT | 46 | 73.3 | (0.007) | 47.4 | (<0.001) | - | - |
| TACE | 142 | 63 | 22.9 | - | ||||
| Su [48] | SBRT | 167 | 62.5 | (0.0047) | (65.1) | (0.29) | Grade 5, 1.2CP + 2 score, 10.1 | 0.11 |
| TACE | 159 | 53.3 | (61) | Grade 5, 1.3CP + 2 score, 4.7 |
CP + 2 score: Elevated Child–Pugh score at two points.